

the oxidation of lipoprotein lipids and other inflammatory mediators, leading to the expression of adhesion molecules such as P-selectin, E-selectin, VCAM1, and ICAM1. These molecules promote the adhesion of monocytes, other leukocytes, and chemotactic factors like CCR2 and CCR5, contributing to the inflammatory response. Disturbed blood flow can also trigger a different form of EC dysfunction known as

through statins, ezetimibe, and PCSK9 inhibitors have shown efficacy in reducing LDL levels, while antisense oligonucleotides targeting Lp(a) present a promising approach for treating high Lp(a) levels. Inflammation plays a critical role in atherosclerosis, and clinical trials targeting IL-1 with neutralizing antibodies have shown promising results. Additionally, modulating B cells and T cells through depletion or vaccination strategies offer potential therapeutic avenues. The advent of CRISPR-based technologies presents exciting possibilities for targeted genome editing, potentially reducing cholesterol levels and exploring gene expression modulation. Age-related processes, such as senescence, have been implicated in atherosclerosis, and senolytics and CAR T cells targeting senescent cells show promise as therapeutic approaches. Modulating gut microbiota through dietary changes and inhibiting specific bacterial lysases may also impact CAD. A holistic understanding of atherosclerosis requires integrating various genetic and environmental factors into a systemic network view. Systems studies based on gene-regulatory coexpression networks allow for the identification of key driver genes, which may be potential targets for novel interventions. These approaches offer the potential to define molecular signals in blood associated with atherosclerosis and identify therapeutic opportunities. In summary, the advancements in understanding atherosclerosis and technical developments present numerous opportunities for the development of novel medical applications. Emphasizing prevention, precision medicine, and targeting key pathways offer hope for more effective therapies and better management of this complex and life-threatening disease.

GÉÀ Ó@æ~æäæÄ ÜÈÀ Û&@ { ääöÙ ÓTÈÀ T\|À CÈÈÀ P [{ { ^À TÀ ÇÇÈFÌ DÀ Û^} ^•&^} &^Èä } ä~ &^äÄ
[çäæäçç^Ä•c!^•Ä&æ~•^•Ä^} ä [c@^|æ|ä~•~ } &çä [] ÈÄRÄ Ö^! [] c [|À CÈÀ ÓÈ [|À Ü&äÄ T^äÄ Ü&äÄ
Ì FNFÌ FÈFÌ JÈÄ
HÈÄ
HÈ

✂ Not applicable.

Author declares no conflict of interest.

References

FÈÄ Ó^! { ~ ä^: Ä ÖÈÄŠ [] ^: Ä ÜÈÄ Üæ&@^& [ÄY T ÈÄXä|æ|ÄRÈÄ T~ äæ } æÄ ÖÈÄ^cæ|ÈÇÇÈÈ [DÄ] ' ~ ^ } &^Ä
[-Ä] [•c] äæ } ääæ|Äc ää~*!^ &^ ää^È ä&@Ä|ä [] ! [c^ä] •Ä [] Ä|ä ääÈ { ^ä äæ^äÄ^*^ } ^Ä^ø } !^••ä [] Ä
ä } Ä • { [[c@Ä { ~ &|Ä^&Ä] •Ä [-Äc@Ä^Ä@~ { æ } Ä& [: [] æ!~ äæ!c^!~ ÈÄ Öæ! ää [çæ•&Ä Ü^•Ä T JIGJ I È
HEHEÄ